Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16209967 | 1.00 | MAP3K12 (1.00) | MAP3K12MAP3K13 | |
| SCHEMBL20147767 | 0.94 | MAP3K12 (0.90) | MAP3K12 | |
| SCHEMBL16216917 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13 | |
| SCHEMBL19273618 | 0.90 | MAP3K12 (0.81) | MAP3K12 | |
| SCHEMBL16210784 | 0.90 | MAP3K12 (1.00) | MAP3K12MAP3K13 | |
| SCHEMBL20340980 | 0.88 | MAP3K12 (0.79) | MAP3K12 | |
| SCHEMBL20115527 | 0.85 | MAP3K12 (0.90) | MAP3K12 | |
| SCHEMBL22051070 | 0.85 | MAP3K12 (1.00) | MAP3K12MAP3K13 | |
| SCHEMBL31674881 | 0.85 | MAP3K12 (1.00) | MAP3K12MAP3K13 | |
| SCHEMBL16210479 | 0.85 | MAP3K12 (1.00) | MAP3K12MAP3K13 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10028954-B2 | Biheteroaryl compounds and uses thereof | GENENTECH, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170239246-A9 | BIHETEROARYL COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170239246-A9 | BIHETEROARYL COMPOUNDS AND USES THEREOF | BCHE, SNCA, XDH | MAP3K12 2230/4885MAP3K13 2147/4885 |
| US-10028954-B2 | Biheteroaryl compounds and uses thereof | BCHE, SNCA, XDH | MAP3K12 2230/4885MAP3K13 2147/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.